Related Experiment Video
Updated: Aug 3, 2026
10:57
The Xenopus Oocyte Cut-open Vaseline Gap Voltage-clamp Technique With Fluorometry
Published on: March 11, 2014
Sex, digitalis, and the sodium pump
Mordecai P Blaustein1, Shawn W Robinson, Stephen S Gottlieb
1Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Molecular Interventions
|March 3, 2004
Summary
Digoxin, a heart failure drug, shows sex-based efficacy differences. Female patients face higher mortality risk, while males appear unaffected, necessitating further research and inclusion of women in clinical trials.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Digitalis, derived from foxglove, has been a long-standing treatment for heart failure.
- Cardiotonic steroids like digitalis function by inhibiting the Na(+),K(+)-ATPase, enhancing cardiac contraction.
- Recent research suggests potential sex-based disparities in digoxin's effectiveness for heart failure.
Purpose of the Study:
- To analyze the reported sex-based differences in digoxin efficacy for heart failure treatment.
- To explore potential mechanisms and explanations for observed gender-specific outcomes.
- To advocate for increased female participation in clinical studies concerning digoxin.
Main Methods:
- Review and discussion of findings from Rathore and colleagues' study on digoxin and sex-based outcomes.
- Exploration of physiological and pharmacological factors that may contribute to sex differences.
- Analysis of clinical trial data regarding digoxin therapy in male and female heart failure patients.
Main Results:
- Female patients in the study exhibited an elevated risk of death with digoxin therapy.
- Male patients did not show a similar increased risk of death associated with digoxin.
- The study highlights a potential differential response to digoxin based on sex.
Conclusions:
- Sex-based differences in digoxin efficacy for heart failure warrant further investigation.
- Understanding these disparities is crucial for optimizing heart failure treatment strategies.
- Greater inclusion of women in clinical research is essential for comprehensive therapeutic development.
More Related Videos
08:31FM Dye Cycling at the Synapse: Comparing High Potassium Depolarization, Electrical and Channelrhodopsin Stimulation
Published on: May 24, 2018
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Related Concept Videos
01:47Primary Active Transport
In contrast to passive transport, active transport involves a substance being moved through membranes in a direction against its concentration or electrochemical gradient. There are two types of active transport: primary active transport and secondary active transport. Primary active transport utilizes chemical energy from ATP to drive protein pumps that are embedded in the cell membrane. With energy from ATP, the pumps transport ions against their electrochemical gradients—a direction they...
01:29Primary Active Transport
In contrast to passive transport, active transport involves a substance being moved through membranes in a direction against its concentration or electrochemical gradient. There are two types of active transport: primary active transport and secondary active transport. Primary active transport utilizes chemical energy from ATP to drive protein pumps embedded in the cell membrane. With energy from ATP, the pumps transport ions against their electrochemical gradients—a direction they would not...
01:19Electrophysiology of Normal Cardiac Rhythm
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase of...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:14Active Transport
Active transport is a critical biological process that allows cells to move solutes against an electrochemical gradient. This process requires direct energy input and is characterized by its selectivity, saturability, and susceptibility to competitive inhibition.
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...